【レポートの概要（一部）】
1. Report Overview
1.1 The Prostate Cancer Therapeutics Market Overview
1.2 Prostate Cancer Therapeutics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. Introduction to Prostate Cancer
2.1 What is Cancer?
2.2 Phenotypic Characteristics of Cancer Cells
2.2.1 Uncontrollable Growth
2.2.2 Loss of Apoptosis Pathways
2.2.3 Lack Differentiation
2.2.4 Increased Angiogenesis
2.2.5 Potential for Metastasis
2.2.6 Genetic Instability
2.3 What Causes Cancer?
2.4 Worldwide Prevalence of Cancer: A Global Picture
2.5 What is Prostate Cancer?
2.6 Worldwide Prevalence of Prostate Cancer: Rapid Global Growth
2.7 Risk Factors for Prostate Cancer
2.8 How is Prostate Cancer Diagnosed?
2.8.1 PSA Testing
2.8.2 Digital Rectal Examination Testing
2.8.3 Prostate Cancer Screening: Beneficial or Costly?
2.8.4 Newly Approved Tests May Improve Diagnosis
2.8.4.1 Prostate Cancer Diagnostics in the Pipeline
2.9 Treatment Sequence for Prostate Cancer
2.9.1 Localised Prostate Cancer: Surgery/Radiation is Most Preferred
2.9.1.1 Brachytherapy
2.9.1.2 Radical Prostatectomy
2.9.1.3 External Beam Radiation Therapy
2.9.1.4 Cryotherapy
2.9.1.5 High-Intensity Focussed Ultrasound (HIFU)
2.9.2 Advanced Local or Metastatic Prostate Cancer: Androgen Deprivation Therapy
2.9.3 Non-Metastatic CRPC: Ketoconazole and Anti-Androgens
2.9.4 Metastatic CRPC: Expanding the Standard Taxotere Treatment Paradigm
2.9.5 First Line Chemotherapy: Docetaxel is a Standard Treatment
2.9.6 Post Docetaxel Therapy: Five FDA Approved Drugs
2.9.7 Second Line Chemotherapy: Jevtana Approved in 2010
3. The Prostate Cancer Therapeutics Market 2014-2024
3.1 The Global Prostate Cancer Therapeutics Market, 2013
3.2 The Global Prostate Cancer Therapeutics Market Forecast, 2014-2024
3.3 The Global Prostate Cancer Therapeutics Market: Drivers and Restraints, 2014-2024
4. The Prostate Cancer Drugs Market 2014-2024
4.1 The Prostate Cancer Drugs Market: Increasing Choice of Drugs will Mean Higher Competition
4.2 The Prostate Cancer Drugs Market, 2013
4.3 Leading Prostate Cancer Drugs: Market Forecast, 2014-2024
4.3.1 The Market Shares of Leading Prostate Cancer Drugs, 2014-2024
4.4 First Generation Chemotherapies
4.4.1 Taxotere (Sanofi)
4.4.1.1 Taxotere Sales, 2013
4.4.1.2 Taxotere Sales Forecast, 2014-2024
4.5 Second Generation Chemotherapies
4.5.1 Jevtana (Sanofi)
4.5.1.1 Jevtana Sales, 2013
4.5.1.2 Jevtana Sales Forecast, 2014-2024
4.6 First Generation Hormones
4.6.1 Casodex (AstraZeneca)
4.6.1.1 Casodex Sales, 2013
4.6.1.2 Casodex Sales Forecast, 2014-2024
4.6.2 Lupron (AbbVie)
4.6.2.1 Lupron Sales, 2013
4.6.2.2 Lupron Sales Forecast, 2014-2024
4.6.3 Zoladex (AstraZeneca)
4.6.3.1 Zoladex Sales, 2013
4.6.3.2 Zoladex Sales Forecast, 2014-2024
4.7 Second Generation Hormones
4.7.1 Zytiga (Johnson & Johnson)
4.7.1.1 Zytiga Sales, 2013
4.7.1.2 Zytiga Sales Forecast, 2014-2024
4.7.2 Xtandi (Medivation/ Astellas Pharma)
4.7.2.1 Xtandi Sales, 2013
4.7.2.2 Xtandi Sales Forecast, 2014-2024
4.8 Immunotherapies
4.8.1 Provenge (Dendreon Corporation)
4.8.1.1 Provenge Sales, 2013
4.8.1.2 Provenge Sales Forecasts, 2014-2024
4.9 Radiopharmaceuticals
4.9.1 Xofigo (Bayer)
4.9.1.1 Xofigo Sales, 2013
4.9.1.2 Xofigo Sales Forecast, 2014-2024
4.10 Other Drugs
4.11 Prostate Cancer Drugs Pipeline, 2014
4.11.1 Phase III Development
4.11.1.1 DCVax-Prostate (NorthWest Biotherapeutics)
4.11.1.2 Tookad Soluble (Steba Biotech)
4.11.1.3 ProstAtak (Advantagene)
4.11.1.4 Tasquinimod (Active biotech AB/Ipsen)
4.11.1.5 Custirsen (Oncogenex/ Teva)
4.11.1.6 Cabozantinib (Exelixis)
4.11.1.7 Prostvac (Bavarian Nordic)
4.11.2 Failed Phase III Drugs
4.11.2.1 Custirsen (OncoGenex)
4.11.2.2 Yervoy (Bristol Myers Squibb)
4.11.2.3 Orteronel (Millenium Pharmaceuticals)
4.11.3 Phase II development
4.11.3.1 GDC-0980 (Roche)
4.11.3.2 GDC-0068 (Roche)
4.11.3.3 PSMA ADC (Progenics Pharmaceuticals)
4.11.3.4 Galeterone (Tokai Pharmaceuticals)
4.11.3.5 OGX-427 (OncoGenex Pharmaceuticals)
4.11.3.6 ARN-509 (Johnson & Johnson)
4.11.3.7 Abituzumab (Dl7E6) (Merck)
4.11.3.8 Ipilimumab (Yervoy) (Bristol Myers Squibb)
4.11.4 Phase I
4.11.4.1 ASG-5ME (Agensys/Seattle Genetics)
4.11.4.2 EMD-525797 (EMD Serono)
4.11.4.3 MGAH22 (MacroGenics)
4.11.4.4 RG7450 (Roche)
4.11.4.5 BAY2010112 (Bayer Pharmaceuticals)
4.11.4.6 BX-201 (Bellicum Pharmaceuticals)
4.12 The Leading Companies in the Prostate Cancer Drugs Market, 2014
4.12.1 Johnson & Johnson (J&J)
4.12.1.1 Sales and Performance Analysis, 2013
4.12.1.2 Pharmaceutical Segment Sales Analysis, 2013
4.12.1.3 Oncology Drugs Sales and Performance Analysis, 2013
4.12.1.4 Pharmaceutical Segment R&D Performance Analysis, 2013
4.12.1.5 Recent M&A Activity
4.12.1.5.1 Acquisition of Aragon Pharmaceuticals
4.12.2 AstraZeneca
4.12.2.1 Sales and Performance Analysis, 2013
4.12.2.2 Pharmaceutical Segment Sales Analysis by Segment, 2013
4.12.2.3 Oncology Drugs Sales and Performance Analysis, 2013
4.12.2.4 R&D Performance Analysis, 2013
4.12.3 Sanofi
4.12.3.1 Sales and Performance Analysis, 2013
4.12.3.2 Sales and Performance Analysis by Segment, 2012
4.12.3.3 Oncology Sales and Performance Analysis, 2013
4.12.3.4 R&D Performance Analysis, 2013
4.12.3.5 Oncology Pipeline Portfolio
4.12.4 AbbVie
4.12.4.1 Sales and Performance Analysis, 2013
4.12.4.2 R&D Performance Analysis, 2013
4.12.4.3 Oncology Portfolio Pipeline Products, 2013
5. The Prostate Cancer Devices Market 2014-2024
5.1 The Prostate Cancer Devices Market 2013
5.2 The Prostate Cancer Devices Market Forecast, 2014-2024
5.2.1 The Market Shares of Leading Prostate Cancer Devices Submarkets, 2014-2024
5.3 The Brachytherapy Market, 2014-2024
5.4 The Radical Prostatectomy Market 2014-2024
5.4.1 Intuitive Surgical’s da Vinci Surgical System will Drive Market Growth
5.5 The External Beam Radiation Therapy Market, 2014-2024
5.6 The HIFU Market, 2014-2024
5.7 The Cryotherapy Market, 2014-2024
5.8 Leading Companies in the Prostate Cancer Devices Market 2014-2024
5.8.1 Varian Medical Systems
5.8.1.1 Sales and Performance Analysis, 2013
5.8.1.2 Oncology Segment Sales Analysis, 2013
5.8.1.3 Sales Analysis by Region, 2013
5.8.1.4 R&D Performance Analysis, 2013
5.8.1.5 Key Oncology Products, 2013
5.8.1.6 Varian and Siemens Partnership: Shaping the Future of Cancer Care
5.8.2 Elekta
5.8.2.1 Sales and Performance Analysis, 2013
5.8.2.2 Sales and Performance Analysis by Region, 2012
5.8.2.3 Elekta and Philips Establish Research Consortium
5.8.2.4 Product Launch and Development, 2013
5.8.3 Theragenics Corporation (acquired by Juniper)
5.8.3.1 Theragenics Sales Performance Analysis, 2012
5.8.3.2 Theragenics Sales Performance by Operation, 2012
5.8.3.3 Theragenics sales and Performance Analysis by Business Unit, 2012
5.8.3.4 Mergers and Acquisitions
5.8.3.4.1 Juniper’s acquisition of Theragenics
5.8.3.4.2 Acquisition of Needle Tech Products
5.8.3.4.3 Acquisition of Galt Medical
5.8.3.4.4 Acquisition of CP Medical
6. The Leading National Markets 2014-2024
6.1 Regional Breakdown of the Prostate Cancer Therapeutics Market, 2013
6.2 The Prostate Cancer Therapeutics Market: Regional Forecast, 2014-2024
6.2.1 Market Shares Forecasts of Leading National Prostate Cancer Therapeutics
Markets, 2014-2024
6.3 The US Prostate Cancer Therapeutics Market 2014-2024: Largest National Market
6.4 The European Prostate Cancer Therapeutics Market, 2013
6.4.1 The European Prostate Cancer Therapeutics Market, 2014-2024
6.4.1.1 The German Prostate Cancer Therapeutics Market, 2014-2024
6.4.1.2 The French Prostate Cancer Therapeutics Market, 2014-2024
6.4.1.3 The UK Prostate Cancer Therapeutics Market, 2014-2024
6.4.1.4 The Spanish Prostate Cancer Therapeutics Market, 2014-2024
6.4.1.5 The Italian Prostate Cancer Therapeutics Market, 2014-2024
6.5 The Japanese Prostate Cancer Therapeutics Market, 2014-2024
6.6 The Brazilian Prostate Cancer Therapeutics Market, 2014-2024
6.7 The Russian Prostate Cancer Therapeutics Market, 2014-2024
6.8 The Indian Prostate Cancer Therapeutics Market, 2014-2024
6.9 The Chinese Prostate Cancer Therapeutics Market, 2014-2024
6.10 The South Korean Prostate Cancer Therapeutics Market, 2014-2024
6.11 The Mexican Prostate Cancer Therapeutics Market, 2014-2024
6.12 The Rest of the World Prostate Cancer Therapeutics Market, 2014-2024
7. Qualitative Analysis of the Prostate Cancer Therapeutics Market 2014-2024
7.1 SWOT Analysis, 2014-2024
7.2 Strengths
7.2.1 Prostate Cancer is a High Profile Disease
7.2.2 Rapidly Expanding Ageing Population
7.2.3 Targeted Therapies can Command Premium Prices
7.2.4 Strong R&D Pipeline
7.2.5 Successful Launches through Partnerships between Small/Big Pharma Companies
7.2.6 Use of Off-label Drugs is Common
7.3 Weaknesses
7.3.1 Prostate Cancer Drugs are Expensive
7.3.2 R&D Failures in Late-stage Development
7.3.3 Controversy Over the Value of New Prostate Cancer Devices
7.3.4 U.S Medical Excise Tax
7.4 Opportunities
7.4.1 Rising Incidence of cancer
7.4.2 Emerging National Markets will Drive Growth
7.4.3 Stem Cells Offer Promise
7.4.4 Advances in Diagnostic Technologies: CTC as a Biomarker
7.5 Threats
7.5.1 Concerns about Efficacy and Toxicity of Drugs
7.5.2 Who will Pay for the High Cost of Drugs and Devices?
7.5.3 Governments Decreasing Healthcare Spending
7.5.4 Increase in Generic Competition
7.5.5 Increase in the Practice of ‘Active Surveillance’
7.6 Porter’s Five Force Analysis
7.6.1 Rivalry Among Competitors [High]
7.6.2 Threat of New Entrants [High]
7.6.3 Power of Suppliers [Low]
7.6.4 Power of Buyers [High]
7.6.5 Threat of Substitutes [Low]
8. Expert Opinions
8.1 Professor Malcolm Mason, Cancer Research UK’s Prostate Cancer Expert
8.1.1 Factors Affecting the Growth of Prostate Cancer
8.1.2 Prostate Cancer: To Treat or Not to Treat?
8.1.3 Alternatives to PSA Testing
8.1.4 A Common Option for Early Stage Prostate Cancer: Radical Prostatectomy
8.1.5 Large Number of Clinical Trials Studying Prostate Cancer
8.1.6 Combination Therapy: Better Survival Rates
8.1.7 Novel Prostate Cancer Drugs: A Question of Cost
8.2 Interview with Hans Kolam, Chief Financial Officer and Helen Tuvesson, Chief Scientific Officer, Active Biotech
8.2.1 Tasquinimod: Phase III Pre-Chemotherapy Study
8.2.2 Tasquinimod: An Innovative Mode of Prostate Cancer Treatment
8.2.3 Active Biotech/Ipsen: Partnerships are Pivotal for Oncology Drug Development
8.2.4 Tasquinimod: Other Indications in the Pipeline
8.2.5 Competitive Landscape of the Prostate Cancer Drugs Market
8.2.6 The Drivers of Growth in the Prostate Market
8.3 Dr. Estuardo Aguilar-Cordova, Co-founder, CEO and Chairman, Advantagene
8.3.1 ProstAtak’s Mechanism for Prostate Cancer Prevention
8.3.2 ProsAtak’s Market Size
8.3.3 Immunotherapy: The Future for Cancer Treatment
8.3.4 Active Surveillance: A growing Trend
9. Conclusions
9.1 The Prostate Cancer Therapeutics Market, 2014-2024
9.2 The US Will Remain the Largest National Market from 2014 to 2024
9.3 Concluding Remarks
【レポート販売概要】
■ タイトル：世界の前立腺がん治療市場予測：前立腺がん治療薬、前立腺がん治療デバイス■ 英文：The Prostate Cancer Therapeutics Market 2014-2024
Opportunities for Leading Companies
■ 発行日：2014年7月
■ 調査会社：visiongain
■ 商品コード：VISG409047
■ 調査対象地域：グローバル
- 世界のデジタル包装（パッケージ）及びラベル市場予測：デジタル印刷企業の見通しThe world market for digital packaging and labelling will reach $8.02bn in 2014. In a global, interconnected economy, where the ease and immediacy of social interactions make the world a smaller place, such trends are also having an impact on how brands communicate with their consumers. Digital solutions in packaging are correlated with the need to rapidly respond to opportunities arising from fas …
- ウェルネス不動産の世界市場2019-2023About this market To maintain wellness among luxurious housing sector, developers are increasingly introducing open-air yoga studios and medicinal gardens with calming herbs and meditation courtyards in their residential projects. Also, wealthy homebuyers demand eco-sensitive abodes that are built with natural products and interior design elements that help promote mental clarity. Furthermore, the …
- 世界のエラストマー塗料市場2015The Global Elastomeric Coating Industry Report 2015 is a professional and in-depth study on the current state of the Elastomeric Coating industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Elastomeric Coating market analysis is provided for the international markets including development trends, compet …
- Eディスカバリの世界市場予測（～2021）The E-Discovery market is expected to grow from USD 7.89 Billion in 2016 to USD 22.62 Billion by 2021, at a Compound Annual Growth Rate (CAGR) of 23.4% during the forecast period. The focus on decreasing the operational budget of legal departments and global increase in litigations is driving the market across all regions. The need to adhere to regulatory policies and laws worldwide and the increa …
- 世界におけるGPS/GNSS市場2013-2023（市場トレンド、開発状況、課題）Synopsis This report offers readers insights into technological developments in the Military GPS/GNSS market, as well as detailed analysis of the changing preferences of military forces around the world. It also identifies the current trends in the changing industry structure and the challenges faced by industry participants. Summary Technological Developments in the global Military GPS/GNSS inclu …
- 燃料タンクの世界市場：材料（HDPE、鉄鋼製、アルミ製）、容量、地域、自動車CNGタンク、自動車SCR市場The global automotive fuel tank market is projected to grow at a CAGR of 5.58% from 2016 to 2021, to reach a market size of USD 17.38 Billion by 2021. The rising global vehicle production, growing trend of vehicle weight reduction, and norms pertaining to evaporative emissions have fueled the demand for automotive fuel tanks across the globe. The high-density polyethylene (HDPE) segment of the aut …
- Cachexia：グローバル臨床試験レビューH2, 2013Cachexia Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “Cachexia Global Clinical Trials Review, H2, 2013" provides data on the Cachexia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cachexia. It includes an overview of the trial numbers and their recruitment status as per the site of trial condu …
- 世界のマシン・ビジョン・システム及び部品市場分析と予測（2013-2018）Machine vision is a technology used to replace or complement manual inspections and measurements with digital cameras and image processing. The technology is used in a variety of different industries to automate the production, increase production speed and yield, and to improve product quality. This industry is a knowledge driven industry which experiences an ever increasing complexity of compone …
- ウイルス不活化の世界市場：製品（キット、試薬、装置、サービス）、用途、方法、エンドユーザー、地域別分析The global viral inactivation market is valued at USD 320.5 Million in 2016 and is expected to grow at a CAGR of 12.3%, to reach USD 573.0 Million by 2021. Viral inactivation is important and mandatory step in the manufacturing process of biological products to remove or inactivate potential contaminant viruses. These biological products are used for the treatment and diagnostic purposes in humans …
- 2014年戦略提言：アメリカの補助的医療施設（ER・OR・ICU）向け診断検査市場This 973-page report contains 153 tables and provides comprehensive analysis of the diagnostic testing markets outside the main hospital laboratory (ERs, ORs, and ICUs). The report includes analysis of the market dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for instrument and consumable suppliers. We trust, thi …
- Mighty River Power Limited：石油・ガスバリューチェーン分析レポート2013Mighty River Power Limited Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "Mighty River Power Limited" Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “Mighty River Power Limited”. The report provides key information relating to oil and gas assets of the company along with its operations across the value chai …
- 2G/3G/4G加入者数、展開現状、インフラ契約データベース2013年4四半期（2G, 3G & 4G Subscriptions, Deployments and Infrastructure Contracts Database Q4’2013）With over 250 commercial network launches and over a thousand LTE-enabled devices available in the market as of December 2013, LTE adoption has considerably gained momentum throughout the globe. Unique market and operator requirements have driven several early LTE launches. Driven by these early launches global LTE subscriptions reached nearly 130 Million in Q4’2013. From an operator viewpoint U.S …
- 医療用セラミックスの世界市場：生体不活性セラミックス、生体活性セラミックス、合成吸収性セラミックスAbout Ceramics Ceramics exclusively developed for use in the medical field are termed as medical ceramics. The chemical and physical properties of the ceramics are attributed in such a way that they are compatible with the internal environment of body. Ceramics are mostly used as bone implants. Technavio’s analysts forecast the global medical ceramics market to grow at a CAGR of 7.06% during the p …
- Eni S.p.A.：石油・ガスバリューチェーン分析レポート2013Eni S.p.A. Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "Eni S.p.A." Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “Eni S.p.A.”. The report provides key information relating to oil and gas assets of the company along with its operations across the value chain. The report examines the company’s business st …
- 世界のPON （Passive Optical Network）装置市場動向（2014-2018）TechNavio’s analysts forecast the Global Passive Optical Network Equipment market will grow at a CAGR of 3.56 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing growth of PON equipment in the APAC region. The Global Passive Optical Network Equipment market has also been witnessing the development of ultra-high-capacity optical networks. H …
